ReviewNaunyn-Schmiedeberg's archives of pharmacology2016
Managing risks in drug discovery: reproducibility of published findings.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biotechnological Applications of Biogenic Nanomaterials from Red Seaweed: A Systematic Review (2014-2024).International journal of molecular sciences · 2025Pooled it
- Reporting of measures against bias in nonclinical published research studies: a journal-based comparison.Research integrity and peer review · 2025Article
- Environmental impacts of drugs against parasitic vector-borne diseases and the need to integrate sustainability into their development and use.Open research Europe · 2024Article
- Reproducibility of drug-induced effects on the contractility of an engineered heart tissue derived from human pluripotent stem cells.Frontiers in pharmacology · 2023Article
- Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery.NPJ systems biology and applications · 2022Article
- Engineering complexity in human tissue models of cancer.Advanced drug delivery reviews · 2022Review
- Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry.Frontiers in psychiatry · 2021Article
- The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites.Toxins · 2019Review
- Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists.Frontiers in pharmacology · 2019Article
- Developments with 3D bioprinting for novel drug discovery.Expert opinion on drug discovery · 2018Review
- Replication Study: Intestinal inflammation targets cancer-inducing activity of the microbiota.eLife · 2018Article
- Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.Cancer prevention research (Philadelphia, Pa.) · 2018Review
- Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.Toxins · 2018Article
- Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.eLife · 2018Article
- Translatability score revisited: differentiation for distinct disease areas.Journal of translational medicine · 2017Review
- Article
- International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.Pharmacological reviews · 2017Review
- Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.eLife · 2017Article
- Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.eLife · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of tremendous advances in biopharmaceutical science and technology, the productivity of pharmaceutical research and development has been steadily declining over the last decades. The reasons for this decline are manifold and range from improved standard of care that is more and more difficult to top to inappropriate management of technical and translational risks along the R&D value chain. In this short review, major types of risks in biopharmaceutical R&D and means to address them will be described. A special focus will be on a risk, i.e., the lack of reproducibility of published information, that has so far not been fully appreciated and systematically analyzed. Measures to improve reproducibility and trust in published information will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.